Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
Sallman, D A, Komrokji, R, Vaupel, C, Cluzeau, T, Geyer, S M, McGraw, K L, Al Ali, N H, Lancet, J, McGinniss, M J, Nahas, S, Smith, A E, Kulasekararaj, A, Mufti, G, List, A, Hall, J, Padron, E
Published in Leukemia (01.03.2016)
Published in Leukemia (01.03.2016)
Get full text
Journal Article
Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells
PATTERSON, S. G, WEI, S, CHEN, X, SALLMAN, D. A, GILVARY, D. L, ZHONG, B, POW-SANG, J, YEATMAN, T, DJEU, J. Y
Published in Oncogene (05.10.2006)
Published in Oncogene (05.10.2006)
Get full text
Journal Article
P551: A PHASE 3, RANDOMIZED, OPEN‐LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53‐MUTANT ACUTE MYELOID LEUKEMIA
Daver, N. G., Vyas, P., Chao, M. P., Xing, G., Renard, C., Ramsingh, G., Sallman, D. A., Wei, A. H.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
P553: A PHASE 2, OPEN‐LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST‐LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA
Vyas, P., Daver, N. G., Chao, M. P., Xing, G., Renard, C., Ramsingh, G., Wei, A. H., Sallman, D. A.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER‐RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
Rajakumaraswamy, N., Gandhi, M., Wei, A. H., Sallman, D. A., Daver, N. G., Mo, S., Iqbal, S., Chen, M., Wang, Y., Vyas, P.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P774: CLINICAL OUTCOMES ASSOCIATED WITH AZACITIDINE MONOTHERAPY FOR TREATMENT‐NAIVE PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROME (HR MDS): A SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSIS
Hasegawa, K., Wei, A. H., Garcia‐Manero, G., Daver, N. G., Rajakumaraswamy, N., Iqbal, S., Chan, R. J., Hu, H., Tse, P., Yan, J., Zoratti, M. J., Xie, F., Sallman, D. A.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
S129: TAKEAIM LEUKEMIA‐ A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA‐4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
Garcia‐Manero, G., Winer, E. S., DeAngelo, D. J., Tarantolo, S., Sallman, D. A., Dugan, J., Groepper, S., Giagounidis, A., Götze, K., Metzeler, K. H., Li, C.‐C., Zhou, L., Martinez, E., Lane, M., Roemeling, R., Bohme, M., Kubasch, A. S., Verma, A., Platzbecker, U.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS
Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S. N., Tanaka, T. N., Zeidner, J. F., Garcia‐Manero, G., Jeyakumar, D., Gu, L., Tan, A., Chao, M., O'Hear, C., Lal, I., Vyas, P., Daver, N.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)
DiNardo, C. D., Foran, J. M., Watts, J. M., Stein, E. M., Botton, S., Fathi, A. T., Prince, G. T., Stone, R. M., Patel, P. A., Roboz, G. J., Arellano, M. L., Erba, H. P., Pigneux, A., Baratam, P., Stuart, R. K., Thomas, X., Lemieux, I. R., Bai, X., Kapsalis, S. M., Garcia‐Manero, G., Sallman, D. A.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO‐MYELOID CLINICAL TRIAL PROGRAM
Zeidan, A. M., Al‐Kali, A., Borate, U., Cluzeau, T., DeZern, A. E., Esteve, J., Giagounidis, A., Kobata, K., Lyons, R., Platzbecker, U., Sallman, D. A., Santini, V., Sanz, G. F., Sekeres, M. A., Wei, A. H., Xiao, Z., Van Hoef, M., Nourry‐Boulot, C., Sadek, I., Ma, F., Iordan, A., Sabo, J., Garcia‐Manero, G.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis
Shah, Savan, Talati, Chetasi, Al Ali, Najla, Padron, Eric, Sallman, David A, Sweet, Kendra L., Lancet, Jeffrey E., List, Alan F., Zuckerman, Kenneth S., Komrokji, Rami S., Kuykendall, Andrew
Published in Blood (08.12.2017)
Published in Blood (08.12.2017)
Get full text
Journal Article
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval
Kuykendall, Andrew T., Talati, Chetasi, Al Ali, Najla, Sweet, Kendra, Padron, Eric, Sallman, David A., Lancet, Jeffrey E., List, Alan F., Zuckerman, Kenneth S., Komrokji, Rami S.
Published in Clinical lymphoma, myeloma and leukemia (01.12.2017)
Published in Clinical lymphoma, myeloma and leukemia (01.12.2017)
Get full text
Journal Article
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Gillis, Nancy K, PharmD, Ball, Markus, PhD, Zhang, Qing, MD, Ma, Zhenjun, PhD, Zhao, YuLong, PhD, Yoder, Sean J, MS, Balasis, Maria E, BS, Mesa, Tania E, BS, Sallman, David A, MD, Lancet, Jeffrey E, Prof, Komrokji, Rami S, Prof, List, Alan F, Prof, McLeod, Howard L, Prof, Alsina, Melissa, Prof, Baz, Rachid, MD, Shain, Kenneth H, MD, Rollison, Dana E, PhD, Padron, Eric, Dr
Published in The lancet oncology (01.01.2017)
Published in The lancet oncology (01.01.2017)
Get full text
Journal Article